How Five Medtech Trends Are Reshaping the Device Industry in 2026

Structural forces in pricing, care delivery, and technology are driving a new era of medtech competition.

---

Executive Summary

The medical technology (medtech) landscape is undergoing accelerated change. Structural forces across global pricing, care delivery, supply chains, clinical pathways, and enabling technologies are reshaping how companies compete and where growth will occur. As the industry looks toward 2026, five trends stand out for their potential to redefine market dynamics and drive long-term strategic decisions. These include the expanding influence of mainland China's volume-based procurement (VBP) policy, the continued migration of procedures to outpatient and ambulatory surgical centers (ASCs), the increasing strategic importance of supply chain resilience, the ripple effects of GLP-1 receptor agonists on metabolic care, and the rise of platform-based competition powered by robotics, imaging, and digital workflows. This analysis explores each trend, its scientific and clinical context, and the broader implications for the biotechnology and healthcare sectors.

---

Introduction

The medtech industry has long been characterized by innovation in medical devices, diagnostics, and therapeutic technologies. However, the forces shaping the market in 2026 are not solely technological. Economic policies, regulatory shifts, demographic changes, and the evolution of care delivery models are intersecting to create a new competitive landscape. For medtech companies, understanding these trends is essential for navigating an era of rising expectations around value, cost-effectiveness, and integration with broader healthcare ecosystems.

This article draws on industry analyses and market intelligence to identify five key medtech trends that are expected to influence the sector in 2026 and beyond.

---

Scientific Background

The medtech sector operates at the intersection of engineering, biology, and clinical medicine. Its trajectory is influenced by advances in materials science, data analytics, artificial intelligence, and minimally invasive techniques. At the same time, market access and reimbursement policies increasingly determine whether innovative technologies reach patients. The trends described in this article reflect a broader shift toward value-based healthcare, where outcomes, efficiency, and cost-effectiveness are paramount.

Mainland China's VBP program, for instance, is part of a global movement toward value-based procurement. Originally designed to expand patient access and reduce costs, VBP has evolved into a complex market-structuring mechanism. Similarly, the migration of procedures to outpatient settings is supported by evidence that many interventions can be safely performed outside traditional hospital environments. Clinical research continues to validate the safety and efficacy of these alternatives, enabling policy changes that favor less costly care settings.

The rise of GLP-1 therapies, meanwhile, is grounded in substantial clinical evidence demonstrating their effectiveness in weight management and glycemic control. These therapies are altering the management of obesity and related comorbidities, which in turn affects procedural volumes and device utilization across multiple therapeutic areas.

---

Research Findings

#### 1. Mainland China's VBP Expansion Redefines Global Market Economics

Mainland China's latest national volume-based procurement round represents one of the most consequential shifts in global medtech pricing. The program, initially focused on expanding patient access and curbing high device costs, has evolved into a powerful market-structuring mechanism. New rules introduce more sophisticated anchor-price logic, deeper price compression, and allocation systems that support domestic manufacturers.

For multinational medtech companies, VBP is no longer a localized policy issue. It is influencing expectations around price, volume, and competitive positioning in markets well beyond mainland China. The program's effects are likely to ripple through global pricing strategies, prompting companies to reassess portfolio positioning and market entry approaches.

#### 2. Outpatient and ASC Settings Become Central to Procedure Strategy

The continued migration of procedures from hospitals to outpatient settings is a defining trend in medtech. The U.S. Centers for Medicare & Medicaid Services (CMS) 2026 Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) Payment System Final Rule reinforces this shift. The ASC Covered Procedure List has been expanded, and the inpatient-only list is being phased out. These changes open the door for higher-acuity procedures, such as cardiac ablation, to move into lower-cost settings when clinically appropriate.

This builds on long-running patterns in orthopedics, general surgery, and other specialties, where ASCs have become critical to growth strategies. As more procedures become ASC-eligible, medtech companies must adapt their commercial models, value propositions, and product designs to meet the needs of diverse sites of service.

#### 3. Global Trade and Supply Chain Pressures Reshape Manufacturing Strategy

Supply chain resilience has become a strategic imperative. Tariff exposure, geopolitical factors, and fluctuating material costs are challenging long-standing assumptions about where and how devices should be produced. Companies are responding by diversifying sourcing, re-evaluating business strategies, and pursuing more flexible multi-region manufacturing footprints.

Larger manufacturers are leveraging scale, integration, and technology investment to buffer against global volatility. These trends could reshape competitive dynamics, as cost structures, supplier concentration, and manufacturing geography become increasingly influential in determining competitive advantage.

#### 4. GLP-1 Therapies Shift Patient Behavior and Reshape Care Pathways

The rapid adoption of glucagon-like peptide-1 (GLP-1) receptor agonists is altering how patients and clinicians approach weight management and related comorbidities. While bariatric surgery remains the most effective intervention for substantial weight loss, GLP-1s have rapidly expanded in popularity, changing referral patterns and influencing demand across adjacent medtech categories.

The impact is not uniform. Certain bariatric procedures are experiencing sharper volume pressure than others, and downstream effects — ranging from diabetes care to sleep apnea to cardiovascular monitoring — are only beginning to emerge. This trend reflects a broader shift in how metabolic disease is managed, with ripple effects across multiple device markets and clinical pathways.

#### 5. Enabling Technologies Drive Platform-Based Competition

Enabling technologies, including robotics, imaging, navigation, and digital workflow software, are reshaping how medtech companies differentiate and compete. These technologies are no longer adjuncts to procedures; they are becoming central to integrated ecosystems that support clinical planning, surgical execution, and postoperative care.

Companies are investing heavily in platform architectures that can anchor entire service lines, strengthen customer relationships, and unlock new data-driven value propositions. Emerging open-platform systems are expanding flexibility and creating new competitive dynamics. This shift is redefining how companies deliver value, engage customers, and create long-term strategic advantage.

---

Industry Impact

The trends described above carry significant implications for the medtech industry:

Pricing and Market Access: VBP expansion forces companies to adapt to more aggressive pricing environments, potentially impacting global revenue projections and product portfolio decisions.
Commercial Models: The shift to outpatient care demands new approaches to sales, marketing, and customer support, as ASCs and other alternative sites have distinct procurement and decision-making processes.
Supply Chain Strategy: Resilience considerations are driving diversification and regionalization of manufacturing, which may increase costs in the short term but reduce long-term risk.
Therapeutic Adjacencies: GLP-1 therapies are creating new opportunities and threats across device categories, from metabolic surgery to monitoring devices, requiring companies to rethink their market strategies.
Technology Investment: Platform-based competition encourages higher investment in digital health and robotics, favoring companies that can integrate these technologies into cohesive ecosystems.

These shifts will also influence investment decisions, as venture capital and corporate R&D funding align with emerging growth areas in outpatient technologies, supply chain resilience, and platform-based innovation.

---

Clinical & Regulatory Perspective

The trends highlighted here intersect with evolving clinical and regulatory landscapes. VBP programs are policy instruments designed to improve access and reduce costs, but they also raise questions about long-term device quality and innovation. The migration to ASCs is supported by clinical evidence indicating that many procedures can be safely performed in lower-acuity settings, yet careful patient selection and outcome monitoring remain essential.

GLP-1 therapies have demonstrated robust clinical benefits, but their long-term impact on surgical outcomes and device-dependent procedures requires ongoing investigation. Regulatory bodies are focusing on real-world evidence to guide decisions about device approvals and post-market surveillance.

Safety and ethical considerations are particularly relevant in supply chain decisions, as companies balance cost pressures with the obligation to ensure high-quality, reliable products. Regulatory frameworks are evolving to address digital technologies and integrated platforms, with particular emphasis on cybersecurity and data privacy.

---

Future Outlook

Looking ahead to the next 5–15 years, the medtech industry is likely to experience continued transformation. Artificial intelligence, precision medicine, and synthetic biology will increasingly intersect with traditional medtech, enabling more personalized and predictive care. The shift toward outpatient and home-based care is expected to accelerate, driven by technological advances and evolving patient preferences.

Platform-based ecosystems will likely become the dominant competitive model, with companies integrating devices, data, and services to create comprehensive solutions. Supply chain resilience will remain a strategic priority, as geopolitical and environmental factors continue to introduce volatility.

The expansion of VBP and similar pricing mechanisms could reshape global market access, requiring companies to develop innovative value-based pricing models. At the same time, the broader adoption of GLP-1 therapies may fundamentally alter the landscape for metabolic and cardiovascular devices, prompting new indications and care pathways.

---

Conclusion

The medtech industry in 2026 is defined by convergence — of policy and technology, data and devices, and value and innovation. The five trends analyzed here illustrate how structural forces are reshaping the competitive landscape, creating both challenges and opportunities. Companies that successfully navigate these dynamics will be those that embrace strategic adaptability, invest in enabling technologies, and align with evolving care delivery models. As the industry continues to evolve, evidence-based decision-making and a deep understanding of market trends will remain essential for sustaining growth and improving patient outcomes.

---

Key Takeaways

China's VBP expansion is redefining global pricing expectations and creating a more competitive environment for multinational medtech firms.
The shift to ASCs is broadening access to care and changing the commercial dynamics for many device categories.
Supply chain resilience has become a top strategic priority, with companies diversifying manufacturing and sourcing.
GLP-1 therapies are reshaping metabolic disease pathways and influencing demand for related devices.
Platform-based competition is driving investment in robotics, imaging, and digital workflows, creating new opportunities for integrated solutions.

---

SEO Keywords

Medtech trends 2026, medical device industry, volume-based procurement, ambulatory surgical centers, GLP-1 therapies, supply chain resilience, platform-based competition, digital health, biotechnology, healthcare innovation,

---

Sources

Clarivate. “5 Medtech Trends to Watch in 2026.” https://clarivate.com/life-sciences-healthcare/blog/5-medtech-trends-to-watch-in-2026